Prognostic factors for favorable outcome in disseminated germ cell tumors.
- 1 March 1986
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 4 (3) , 400-407
- https://doi.org/10.1200/jco.1986.4.3.400
Abstract
Between 1978 and 1982, 180 patients from Indiana University (indianapolis [USA]) were entered on the Southeastern Cancer Study Group (SECSG) protocal 78 GU 240, a randomized comparison of cisplatin, vinblastine, and bleomycin (PVB) v PVB plus doxorubicin induction chemotherapy regimens, with a second randomization to maintenance vinblastine v no further therapy. One hundred forty-eight of these patients obtained a favorable response to chemotherapy, defined as a complete response (CR) or a surgical resection of teratoma. The prognostic significance of various patient characteristics was investigated using the logistic regression model. Two classifications for the extent of disease were considered: the Indian staging system and the M.D. Anderson (MDA) staging system. The Indiana staging system had the greater prognostic significance. This staging system allowed the population to be split into three groups (minimal, moderate, advanced disease) in which the observed proportions of favorable responders were 99%, 90%, and 58%, respectively. Within the advanced group, the number of elevated tumor markers subdivided these patients into three groups, with the observed proportions of favorable responders being 73%, 65%, and 45%. The Indiana and MDA staging systems were subsequently prospectively used in SECSG protocal GU 81 332, a study randomizing patients to remission induction therapy with PVB v cisplatin, VP-16, and bleomycin. The prognostic value of the Indiana staging system was prospectively validated in this study.This publication has 5 references indexed in Scilit:
- The prognostic significance of endodermal sinus tumor histology among patients treated for stage III nonseminomatous germ cell tumors of the testesCancer, 1984
- Treatment of poor prognosis nonseminomatous testicular cancer with a “high-dose” platinum combination chemotherapy regimenCancer, 1983
- MULTIVARIATE-ANALYSIS OF PROGNOSTIC VARIABLES IN PATIENTS WITH METASTATIC TESTICULAR CANCER1983
- The Role of Maintenance Therapy in Disseminated Testicular CancerNew England Journal of Medicine, 1981
- Vinblastine (VLB), bleomycin (BLEO), cis-diamminedichloroplatinum (DDP) in disseminated extragonadal germ cell tumors. A southwest oncology group studyCancer, 1980